

Company Overview

Cellceutix Corp is a biopharmaceutical company. The Company is engaged in the business of developing small molecule therapies to treat diseases in the areas of cancer, dermatology, infections, and inflammatory disease.

More Info

Exceptionally strong pipeline, novel mechanisms of action

Three compounds in four clinical trials:

- Brilacidin: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (phase 2b complete, preparing for phase 3), oral mucositis (phase 2)
- Kevetrin: advanced solid tumors (phase 1), preparing phase 2 for ovarian cancer
- Prurisol: psoriasis (phase 2)

FDA designations for expedited drug development

- Fast Track: Brilacidin-OM for oral mucositis
- Orphan Drug: Kevetrin for ovarian cancer, Kevetrin for retinoblastoma
- Pediatric Rare Disease: Kevetrin for retinoblastoma
- Qualified Infectious Disease Product: Brilacidin for ABSSSI

Balance Sheet

	Jun-15	Jun-14
Total Cash	8,410	4,988
Debt	2,022	2,022
Long-Term Debt	N/A	N/A
Shareholder's Equity	7,024	1,206
Current Ratio	1.20	0.58
Working Capital	1.5m	-4.1m

Income Statement

	Jun-15	Jun-14
Revenue	0.00	0.00
Operating Income	-12,956	-8,038
Net Income	-13,145	-10,227

*USD in Thousands except per share data

Stock Information



Symbol
CTIX (OTCQB)

Prev Close
1.2600

Location
Beverly, MA

30-Day Avg Volume
140,911

Sector
Healthcare

52-Week Range
0.9412 - 2.1000

Industry
Biotechnology

Year End
Dec 31, 2015

Market Cap
154,400,000

Cash Position
8,410.00

Shares Outstanding
122,540,536

Inside Ownership
10.70%

Website
<http://www.cellceutix.com>

Company Contact

Investor relations
info@cellceutix.com

Recent News & Headlines

[Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Ph...](#)
Marketwired • August 3, 2016

[Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis](#)
Marketwired • July 21, 2016

[Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative...](#)
Marketwired • July 18, 2016